<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cabozantinib: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cabozantinib: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cabozantinib: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="87616" href="/d/html/87616.html" rel="external">see "Cabozantinib: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="134128" href="/d/html/134128.html" rel="external">see "Cabozantinib: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F16047819"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cabometyx;</li>
<li>Cometriq (100 MG Daily Dose);</li>
<li>Cometriq (140 MG Daily Dose);</li>
<li>Cometriq (60 MG Daily Dose)</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871532"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Cabometyx</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F15674860"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Tyrosine Kinase Inhibitor;</li>
<li>
                        Antineoplastic Agent, Vascular Endothelial Growth Factor (VEGF) Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F15846538"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Do not substitute cabozantinib tablets (Cabometyx) and capsules (Cometriq). Cabozantinib is associated with a moderate or high emetic potential; antiemetics are recommended to prevent nausea/vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>). Withhold cabozantinib treatment for at least 3 weeks prior to scheduled surgery (including dental surgery or invasive dental procedures); do not administer cabozantinib for at least 2 weeks after major surgery and until adequate wound healing. Do not use cabozantinib in patients with a recent history of hemorrhage (including hemoptysis, hematemesis, or melena). Do not initiate cabozantinib in patients with uncontrolled hypertension.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d807adbd-d5e1-4670-a241-7a1012c77d9e">Hepatocellular carcinoma, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatocellular carcinoma, advanced: Cabometyx:</b>
<b>Oral: </b>60 mg once daily until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29972759']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29972759'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="01ba1574-d28e-491e-b878-10259e42f21d">Renal cell carcinoma, advanced, first-line combination therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal cell carcinoma, advanced, first-line combination therapy (Cabometyx):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May be used in combination with nivolumab regardless of risk stratification (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33657295']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33657295'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 40 mg once daily (in combination with nivolumab); continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33657295']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33657295'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2fd55adb-d78f-4989-a26a-aa271908061d">Renal cell carcinoma, advanced, single-agent therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal cell carcinoma, advanced, single-agent therapy (Cabometyx): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May be used in patients who are ineligible for (or who decline) initial treatment with immunotherapy-based combinations, as well as in those with progression after initial immunotherapy-based options or other VEGFR tyrosine kinase inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27279544','lexi-content-ref-George.1','lexi-content-ref-32599410']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27279544','lexi-content-ref-George.1','lexi-content-ref-32599410'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 60 mg once daily until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26406150','lexi-content-ref-28199818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26406150','lexi-content-ref-28199818'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2c6684a5-f998-4322-ba8a-d9337fae0e48">Thyroid cancer, differentiated, locally advanced or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid cancer, differentiated, locally advanced or metastatic: Cabometyx: Oral: </b>60 mg once daily until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34237250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34237250'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b8ec153c-7054-4a05-a527-48ade7b54c66">Thyroid cancer, medullary, metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid cancer, medullary, metastatic: Cometriq:</b>
<b>Oral:</b> 140 mg once daily until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29045520']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29045520'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Missed doses:</i></b> Do not take a missed dose within 12 hours of the next dose.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991518"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal impairment prior to treatment initiation</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>The estimated glomerular filtration rate (eGFR) is estimated using MDRD (modification of diet in renal disease) equation.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup> or dialysis: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal toxicity during treatment: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Proteinuria, grade 2 or 3: Withhold cabozantinib until improvement to ≤ grade 1 proteinuria, then resume at a reduced dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Nephrotic syndrome: Permanently discontinue cabozantinib.</p></div>
<div class="block doha drugH1Div" id="F50988999"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment prior to treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (Child-Pugh class A):</p>
<p style="text-indent:-2em;margin-left:6em;">Cabometyx: No dosage adjustment is necessary</p>
<p style="text-indent:-2em;margin-left:6em;">Cometriq: Reduce the initial dose to 80 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate impairment (Child-Pugh class B):</p>
<p style="text-indent:-2em;margin-left:6em;">Cabometyx:</p>
<p style="text-indent:-2em;margin-left:8em;">Initial dose 60 mg once daily: Reduce dose to 40 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">Initial dose 40 mg once daily: Reduce dose to 20 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Cometriq: Reduce the initial dose to 80 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (Child-Pugh class C): Avoid use (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatotoxicity during treatment (when used in combination with nivolumab [Cabometyx]):</b></p>
<p style="text-indent:-2em;margin-left:4em;">ALT or AST &gt;3 to ≤10 times ULN with concurrent total bilirubin &lt;2 times ULN: Withhold both cabozantinib and nivolumab; consider corticosteroid therapy. Upon recovery to grade 0 or 1, may consider rechallenging with cabozantinib (at a reduced dose based on the severity) and/or nivolumab.</p>
<p style="text-indent:-2em;margin-left:4em;">ALT or AST &gt;10 times ULN or &gt;3 times ULN with concurrent total bilirubin ≥2 times ULN: Permanently discontinue both cabozantinib and nivolumab; consider corticosteroid therapy.</p></div>
<div class="block dot drugH1Div" id="F15846539"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Cabozantinib Dose Reduction Levels for Adverse Reactions</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Initial dose</p></th>
<th align="center">
<p style="text-indent:0em;">First dose reduction</p></th>
<th align="center">
<p style="text-indent:0em;">Second dose reduction</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:-2em;margin-left:2em;">
<sup>a </sup>If previously receiving the lowest dose, resume at the same dose. If lowest dose is not tolerated, discontinue cabozantinib.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<b>Cabometyx</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">60 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">40 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">20 mg once daily<sup>a</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">40 mg once daily (in combination with nivolumab)</p></td>
<td align="center">
<p style="text-indent:0em;">20 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">20 mg every other day<sup>a</sup></p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<b>Cometriq</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">140 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">100 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">60 mg once daily<sup>a</sup></p></td></tr></tbody></table>
<table border="1" frame="border" rules="all">
<caption>
<b></b>
<b>Cabozantinib</b>
<b> Recommended Dosage Modifications for Adverse Reactions</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Adverse reaction</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Severity</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Cabobetyx dosage modification </b></p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>If cabozantinib is discontinued, a drop in BP is expected and antihypertensive therapy should be reduced and/or interrupted as clinically appropriate (ESC [Lyon 2022]).</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adrenal insufficiency (when used in combination with nivolumab)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥ grade 2</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initiate symptomatic treatment (including hormone replacement therapy as clinically indicated). Withhold cabozantinib (and/or nivolumab); resume cabozantinib at a reduced dose depending on the severity.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">GI toxicity: Diarrhea</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Any grade</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Manage with antidiarrheals as indicated.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 2, 3, or 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold cabozantinib until ≤ grade 1, then resume at a reduced dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">GI toxicity: Perforation or fistulas</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">GI perforation (any grade) or grade 4 fistula</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Permanently discontinue cabozantinib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Hematologic toxicity (Cometriq)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold cabozantinib; upon return to baseline or improvement to grade 1, resume at a reduced dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Hemorrhage</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Permanently discontinue cabozantinib.</p></td></tr>
<tr>
<td align="center" rowspan="4">
<p style="text-indent:0em;text-align:left;">Hypertension</p></td>
<td align="center" colspan="2">
<p style="text-indent:0em;text-align:left;">If indicated, initiate appropriate antihypertensive therapy<sup>a</sup> to reduce the risk for cardiovascular complications (ASCO [Armenian 2017]; ESC [Lyon 2022]).</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold cabozantinib until hypertension is adequately controlled to ≤ grade 2, then resume at a reduced dose. Permanently discontinue cabozantinib for hypertension that cannot be controlled.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Permanently discontinue cabozantinib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Hypertensive crisis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Permanently discontinue cabozantinib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Hypocalcemia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Any</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Replace calcium as necessary during treatment. Depending on the severity, withhold cabozantinib and resume at a reduced dose upon recovery or permanently discontinue.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Osteonecrosis of the jaw</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Any grade</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold cabozantinib until complete resolution, then resume at a reduced dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Palmar-plantar erythrodysesthesia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 2 (intolerable) or grade 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold cabozantinib until ≤ grade 1, then resume at a reduced dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Reversible posterior leukoencephalopathy syndrome</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Any grade</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Permanently discontinue cabozantinib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Thromboembolic events</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Acute myocardial infarction (any grade), cerebral infarction (≥ grade 2), arterial thromboembolic events (grade 3 or 4), venous thromboembolic events (grade 4)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Permanently discontinue cabozantinib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Thyroid dysfunction</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Any</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Manage thyroid dysfunction as clinically indicated.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Wound healing complications</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Any</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold cabozantinib treatment for at least 3 weeks prior to scheduled surgery (including dental surgery or invasive dental procedures); do not administer cabozantinib for at least 2 weeks after major surgery and until adequate wound healing. The safety of resuming cabozantinib after resolution of wound healing complications has not been established.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Other adverse reactions</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 2 (intolerable), 3, or 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold cabozantinib until ≤ grade 1 or baseline, then resume at a reduced dose.</p></td></tr></tbody></table></div>
<div class="block dop drugH1Div" id="F56250138"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="134128" href="/d/html/134128.html" rel="external">see "Cabozantinib: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Do not substitute cabozantinib tablets (Cabometyx) and capsules (Cometriq). Antiemetics are recommended as clinically appropriate for the prophylaxis and treatment of nausea and vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34237250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34237250'])">Ref</a></span>). Withhold cabozantinib treatment for at least 3 weeks prior to scheduled surgery (including dental surgery or invasive dental procedures); do not administer cabozantinib for at least 2 weeks after major surgery and until adequate wound healing. Do not use cabozantinib in patients with a recent history of hemorrhage (including hemoptysis, hematemesis, or melena).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2c6684a5-f998-4322-ba8a-d9337fae0e48">Thyroid cancer, differentiated, locally advanced or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid cancer, differentiated, locally advanced or metastatic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Cabometyx: Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">BSA &lt;1.2 m<sup>2</sup>: Oral: 40 mg once daily until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:6em;">BSA ≥1.2 m<sup>2</sup>: Oral: 60 mg once daily until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for toxicity:</b> Cabometyx:</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption>
<b>Cabozantinib Dose Reduction Levels for Adverse Reactions</b></caption>
<colgroup><col/>
<col/>
<col/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;">Initial Dosage</p></th>
<th align="left">
<p style="text-indent:0em;">First Dosage Reduction</p></th>
<th align="left">
<p style="text-indent:0em;">Second Dosage Reduction</p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> If previously receiving the lowest dose, resume at the same dose. If lowest dose is not tolerated, discontinue cabozantinib.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;">40 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;">20 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;">20 mg every other day<sup>a</sup></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">60 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;">40 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;">20 mg once daily<sup>a</sup></p></td></tr></tbody></table>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption>
<b>Cabozantinib Recommended Dosage Modifications for Adverse Reactions</b></caption>
<colgroup><col/>
<col/>
<col/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Adverse Reaction</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Severity</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Cabometyx Dosage Modification </b></p></th></tr></thead>
<tbody>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">GI toxicity: Diarrhea</p></td>
<td align="left">
<p style="text-indent:0em;">Any grade</p></td>
<td align="left">
<p style="text-indent:0em;">Manage with antidiarrheals as indicated.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grades 2, 3, or 4</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold cabozantinib until ≤ grade 1, then resume at a reduced dose.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">GI toxicity: Perforation or fistulas</p></td>
<td align="left">
<p style="text-indent:0em;">GI perforation (any grade) or grade 4 fistula</p></td>
<td align="left">
<p style="text-indent:0em;">Permanently discontinue cabozantinib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Hemorrhage</p></td>
<td align="left">
<p style="text-indent:0em;">Grade 3 or 4</p></td>
<td align="left">
<p style="text-indent:0em;">Permanently discontinue cabozantinib.</p></td></tr>
<tr>
<td align="left" rowspan="3">
<p style="text-indent:0em;">Hypertension</p></td>
<td align="left">
<p style="text-indent:0em;">Grade 3</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold cabozantinib until hypertension is adequately controlled to ≤ grade 2, then resume at a reduced dose. Permanently discontinue cabozantinib for hypertension that cannot be controlled.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 4</p></td>
<td align="left">
<p style="text-indent:0em;">Permanently discontinue cabozantinib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Hypertensive crisis</p></td>
<td align="left">
<p style="text-indent:0em;">Permanently discontinue cabozantinib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Hypocalcemia</p></td>
<td align="left">
<p style="text-indent:0em;">Any</p></td>
<td align="left">
<p style="text-indent:0em;">Replace calcium as necessary during treatment. Depending on the severity, withhold cabozantinib and resume at a reduced dose upon recovery or permanently discontinue.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Osteonecrosis of the jaw</p></td>
<td align="left">
<p style="text-indent:0em;">Any grade</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold cabozantinib until complete resolution, then resume at a reduced dose.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Palmar-plantar erythrodysesthesia</p></td>
<td align="left">
<p style="text-indent:0em;">Grade 2 (intolerable) or grade 3</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold cabozantinib until ≤ grade 1, then resume at a reduced dose.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Reversible posterior leukoencephalopathy syndrome</p></td>
<td align="left">
<p style="text-indent:0em;">Any grade</p></td>
<td align="left">
<p style="text-indent:0em;">Permanently discontinue cabozantinib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Thromboembolic events</p></td>
<td align="left">
<p style="text-indent:0em;">Acute myocardial infarction (any grade), cerebral infarction (≥ grade 2), arterial thromboembolic events (grade 3 or 4), venous thromboembolic events (grade 4)</p></td>
<td align="left">
<p style="text-indent:0em;">Permanently discontinue cabozantinib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Thyroid dysfunction</p></td>
<td align="left">
<p style="text-indent:0em;">Any</p></td>
<td align="left">
<p style="text-indent:0em;">Manage thyroid dysfunction as clinically indicated.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Wound healing complications</p></td>
<td align="left">
<p style="text-indent:0em;">Any</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold cabozantinib treatment for at least 3 weeks prior to scheduled surgery (including dental surgery or invasive dental procedures); do not administer cabozantinib for at least 2 weeks after major surgery and until adequate wound healing. The safety of resuming cabozantinib after resolution of wound healing complications has not been established.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Other adverse reactions</p></td>
<td align="left">
<p style="text-indent:0em;">Grade 2 (intolerable), grade 3 or 4</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold cabozantinib until ≤ grade 1 or baseline, then resume at a reduced dose.</p></td></tr></tbody></table></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F56250199"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Renal impairment prior to treatment initiation</i>
<i>:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Cabometyx: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup> or dialysis: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Renal toxicity during treatment: </i></p>
<p style="text-indent:-2em;margin-left:4em;">Proteinuria, grade 2 or 3: Withhold cabozantinib until improvement to ≤ grade 1 proteinuria, then resume at a reduced dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Nephrotic syndrome: Permanently discontinue cabozantinib.</p></div>
<div class="block dohp drugH1Div" id="F56250202"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatic impairment prior to treatment initiation:</i> Cabometyx: Children ≥12 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate impairment:</p>
<p style="text-indent:-2em;margin-left:6em;">BSA &lt;1.2 m<sup>2</sup>: Reduce initial dose to 20 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">BSA ≥1.2 m<sup>2</sup>: Reduce initial dose to 40 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: Avoid use (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F15809126"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions report in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (30% to 61%, including hypertensive crisis)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (16%), erythema of skin (11%), hair discoloration (34%), palmar-plantar erythrodysesthesia (42% to 50%), skin rash (19% to 23%), xeroderma (11% to 19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia (37%), hypoalbuminemia (19% to 51%), hypocalcemia (8% to 52%), hypokalemia (18% to 23%), hypomagnesemia (19% to 31%), hyponatremia (10% to 30%), hypophosphatemia (25% to 48%), hypothyroidism (8% to 21%), increased lactate dehydrogenase (84% to 90%), increased serum triglycerides (53%), weight loss (17% to 48%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (23% to 27%), constipation (25% to 27%), decreased appetite (23% to 48%), diarrhea (51% to 74%; grades 3/4: 7% to 16%), dysgeusia (10% to 34%), dyspepsia (10% to 12%), dysphagia (13%), increased serum amylase (16%), mouth pain (36%), mucosal swelling (14% to 19%), nausea (24% to 50%; grades 3/4: 1% to 4%), stomatitis (13% to 51%; grades 3/4: 2% to 5%), vomiting (14% to 32%; grades 3/4: ≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Proteinuria (2% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (17% to 31%; grades 3/4: 4% to 5%), leukopenia (35%; grades 3/4: &lt;1%), lymphocytopenia (25% to 53%; grades 3/4: 7% to 16%), neutropenia (31% to 43%; grades 3/4: 2% to 7%), thrombocytopenia (25% to 35%; grades 3/4: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hyperbilirubinemia (12% to 25%), increased gamma-glutamyl transferase (26% to 27%), increased serum alanine aminotransferase (66% to 86%), increased serum alkaline phosphatase (34% to 52%), increased serum aspartate aminotransferase (73% to 86%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (19% to 22%), dizziness (11% to 14%), fatigue (41% to 56%), headache (10% to 18%), voice disorder (10% to 20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (11% to 14%), limb pain (9% to 14%), muscle spasm (8% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (58%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (18%), dyspnea (12% to 19%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Arterial thromboembolism (2%), hypotension (7%), pulmonary embolism (4% to 5%), venous thromboembolism (6% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hyperkeratosis (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastrointestinal fistula (1%), gastrointestinal perforation (1% to 3%), hemorrhoids (9%), xerostomia (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemorrhage (grades ≥3: 3% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (9%), paresthesia (7%), peripheral neuropathy (5%), peripheral sensory neuropathy (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Musculoskeletal chest pain (9%), osteonecrosis of the jaw (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pleural effusion (≥2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fistula (nongastrointestinal: 1% to 4%, including transesophageal fistula), postoperative wound complication (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic hepatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Reversible posterior leukoencephalopathy syndrome, seizure</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Renal: Nephrotic syndrome</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Cardiovascular: Aneurysm (arterial), aortic aneurysm, aortic dissection, coronary artery dissection, myocardial rupture (arterial rupture and aortic rupture)</p></div>
<div class="block coi drugH1Div" id="F15840645"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling</i>: Hypersensitivity to cabozantinib or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F15840658"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal insufficiency: Primary and secondary adrenal insufficiency have occurred with the combination of cabozantinib and nivolumab, including cases of grade 2 to 3 adrenal insufficiency. The majority of patients received hormone replacement therapy, including systemic corticosteroids. Adrenal insufficiency resolved in approximately one-fourth of patients. In cases where cabozantinib and nivolumab were withheld for adrenal insufficiency, most reinitiated treatment after symptom improvement with recurrence of adrenal insufficiency in some patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic toxicity: Palmar-plantar erythrodysesthesia syndrome occurred in nearly half of patients; grade 3 events were reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI toxicity: Diarrhea has been commonly observed in cabozantinib-treated patients; grade 3 and 4 diarrhea has occurred. GI perforations and fistulas (including fatal cases) have been reported with cabozantinib. Tracheal/esophageal fistulas were also noted; some cases were fatal.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemorrhage: Severe and fatal hemorrhages have occurred with cabozantinib, including grade 3 or higher events.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Increased frequencies of grade 3 and 4 ALT and AST elevations may occur when cabozantinib is administered in combination with nivolumab (compared to cabozantinib alone). ALT or AST elevations may recur when rechallenged with cabozantinib and/or nivolumab.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertension: Cabozantinib may increase the risk of treatment-emergent hypertension. Stage 1 and 2 hypertension were commonly seen in cabozantinib-treated patients; grade 3 and 4 hypertension has been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypocalcemia: Cabozantinib may cause hypocalcemia, including grade 3 and 4 events.</p>
<p style="text-indent:-2em;margin-left:4em;">• Osteonecrosis of the jaw: Osteonecrosis of the jaw (ONJ) occurred rarely; manifestations may include jaw pain, osteomyelitis, osteitis, bone erosion, tooth or periodontal infection, toothache, gingival ulceration or erosion, persistent jaw pain or slow healing of the mouth or jaw after dental surgery.</p>
<p style="text-indent:-2em;margin-left:4em;">• Proteinuria: Proteinuria occurred in some patients receiving cabozantinib; nephrotic syndrome was also reported (rare).</p>
<p style="text-indent:-2em;margin-left:4em;">• Reversible posterior leukoencephalopathy syndrome: Reversible posterior leukoencephalopathy syndrome (RPLS), a syndrome of subcortical vasogenic edema (based on MRI findings), may occur with cabozantinib. Signs of RPLS include seizures, headache, visual disturbances, confusion, or altered mental function.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolic events: Cabozantinib is associated with an increased risk of thrombotic events. Venous thromboembolism (including pulmonary embolism) and arterial thromboembolism have been observed in cabozantinib-treated patients. Fatal thromboembolic events have occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid dysfunction: Thyroid dysfunction (primarily hypothyroidism) has been observed with cabozantinib, including grade 3 thyroid dysfunction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Wound healing impairment: Cabozantinib inhibits vascular endothelial growth factor receptors 1, 2, and 3; wound healing complications have been reported with therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Formulations: Cabozantinib is available in tablets (Cabometyx) and capsules (Cometriq) which are NOT interchangeable; do NOT substitute.</p></div>
<div class="block foc drugH1Div" id="F16047820"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cometriq (100 MG Daily Dose): Capsules: 100 mg daily-dose: 80 mg (7s) and 20 mg (7s)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cometriq (140 MG Daily Dose): Capsules: 140 mg daily-dose: 80 mg (7s) and 20 mg (21s)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cometriq (60 MG Daily Dose): Capsules: 60 mg daily-dose: 20 mg (21s)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cabometyx: 20 mg, 40 mg, 60 mg</p></div>
<div class="block geq drugH1Div" id="F52175099"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16570462"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Cometriq (100 MG Daily Dose) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 &amp; 20 mg (per each): $415.27</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Cometriq (140 MG Daily Dose) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 x 20 MG &amp;80 MG (per each): $207.64</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Cometriq (60 MG Daily Dose) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $276.85</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Cabometyx Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $1,023.39</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $1,023.39</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $1,023.39</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871533"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cabometyx: 20 mg, 40 mg, 60 mg</p></div>
<div class="block accres drugH1Div" id="F16058319"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Contact Exelixus Access Services for information on obtaining cabozantinib (855-253-3273).</p></div>
<div class="block adm drugH1Div" id="F15846579"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Do not administer with food; administer on an empty stomach (at least 1 hour before or 2 hours after eating). <b>Note:</b> The prescribing information (for Cometriq) describes when to give food with respect to cabozantinib; no food should be consumed for at least 2 hours before or for at least 1 hour after the cabozantinib dose. Swallow whole; do not open capsules or crush tablets. Do not substitute cabozantinib tablets and capsules.</p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib is associated with a moderate or high emetic potential; antiemetics are recommended to prevent nausea/vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F56250209"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer on an empty stomach (at least 1 hour before or 2 hours after eating). Swallow whole; do not crush tablets. Do not substitute cabozantinib tablets and capsules. Antiemetics are recommended as clinically appropriate for the prophylaxis and treatment of nausea and vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34237250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34237250'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses:</i> Do not take a missed dose within 12 hours of the next dose.</p></div>
<div class="block hazard drugH1Div" id="F49104438"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F15674862"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatocellular carcinoma, advanced (Cabometyx):</b> Treatment of hepatocellular carcinoma (HCC) in patients who have previously been treated with sorafenib.</p>
<p style="text-indent:-2em;margin-left:4em;">According to guidelines from the American Society of Clinical Oncology for systemic therapy for advanced HCC, cabozantinib is a potential second-line therapy option in patients who received atezolizumab and bevacizumab as first-line therapy, although sorafenib or lenvatinib are preferred in this setting. Cabozantinib is also a second-line therapy option in patients who received first-line therapy with sorafenib or lenvatinib (ASCO [Gordan 2020]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal cell carcinoma, advanced (Cabometyx):</b></p>
<p style="text-indent:-2em;margin-left:4em;">First-line treatment (in combination with nivolumab) of advanced renal cell carcinoma (RCC).</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment (monotherapy) of advanced RCC.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid cancer, differentiated, locally advanced or metastatic (Cabometyx):</b> Treatment of locally advanced or metastatic differentiated thyroid cancer that has progressed following VEGFR-targeted therapy in adults and pediatric patients ≥12 years of age who are radioactive iodine-refractory or ineligible.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid cancer, medullary (Cometriq):</b> Treatment of progressive, metastatic medullary thyroid cancer.</p></div>
<div class="block mst drugH1Div" id="F15838145"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Cabozantinib may be confused with axitinib, bosutinib, cabazitaxel, capecitabine, capmatinib, ceritinib, cobimetinib, crizotinib, dasatinib, imatinib, lenvatinib, nilotinib, ponatinib, regorafenib, ruxolitinib, vandetanib, vemurafenib.</p>
<p style="text-indent:-2em;margin-left:4em;">Cabometyx may be confused with Cometriq, Copiktra.</p>
<p style="text-indent:-2em;margin-left:4em;">Cometriq may be confused with CoQ10 (abbreviation often used for coenzyme Q10).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medical Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Cabozantinib tablets (Cabometyx) and capsules (Cometriq) are NOT interchangeable; do NOT substitute.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F16061023"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C9 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F16061021"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Androgens: Hypertension-Associated Agents may enhance the hypertensive effect of Androgens. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisphosphonate Derivatives: Angiogenesis Inhibitors (Systemic) may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Specifically, the risk for osteonecrosis of the jaw may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Cabozantinib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Cabozantinib. Management: Avoid use of strong CYP3A4 inducers with cabozantinib if possible. If combined, increase cabozantinib capsules (Cometriq) by 40 mg from previous dose, max 180 mg daily. Increase cabozantinib tablets (Cabometyx) by 20 mg from previous dose, max 80 mg daily<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Cabozantinib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Cabozantinib. Management: Avoid use of a strong CYP3A4 inhibitor with cabozantinib if possible. If combined, decrease cabozantinib capsules (Cometriq) by 40 mg from previous dose or decrease cabozantinib tablets (Cabometyx) by 20 mg from previous dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May increase the serum concentration of Cabozantinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MRP2 Inhibitors: May increase the serum concentration of Cabozantinib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifabutin: May decrease the serum concentration of Cabozantinib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifapentine: May decrease the serum concentration of Cabozantinib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: May enhance the hypertensive effect of Hypertension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May decrease the serum concentration of Cabozantinib.<i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F15846439"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">A high-fat meal increased C<sub>max</sub> and AUC by 41% and 57%, respectively compared to the fasted state. Cabozantinib serum concentrations may be increased when taken with grapefruit or grapefruit juice. Management: Must be taken on an empty stomach, at least 1 hour before and 2 hours after food. Avoid concurrent use with grapefruit or grapefruit juice.</p></div>
<div class="block rep_considerations drugH1Div" id="F49295129"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Evaluate pregnancy status prior to initiating therapy in patients who can become pregnant. Patients who can become pregnant should use effective contraception during therapy and for 4 months after the last cabozantinib dose.</p></div>
<div class="block pri drugH1Div" id="F15840642"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on its mechanism of action and data from animal reproduction studies, adverse effects on pregnancy may be expected.</p></div>
<div class="block brc drugH1Div" id="F15840644"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if cabozantinib is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends discontinuing breastfeeding during treatment and for 4 months after the last cabozantinib dose.</p></div>
<div class="block dic drugH1Div" id="F15846578"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Avoid grapefruit and grapefruit juice throughout therapy.</p></div>
<div class="block mop drugH1Div" id="F15846581"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Monitor renal function, liver function (at baseline and periodically; consider monitoring more frequently when cabozantinib is administered in combination with nivolumab), CBC with differential and platelets, serum electrolytes, including calcium (regularly during treatment), thyroid function testing (at baseline and as clinically indicated). Monitor urine protein (regularly during treatment). Consider monitoring urine protein/creatinine ratio (at baseline and as clinically indicated) (Brose 2021). Evaluate pregnancy status (prior to treatment in patients who can become pregnant). Monitor BP (regularly during therapy). Monitor for signs/symptoms of GI perforations or fistulas (including abscess and sepsis), bleeding/hemorrhage, palmar-plantar erythrodysesthesia syndrome, reversible posterior leukoencephalopathy syndrome (evaluate patients who present with seizures, headache, visual disturbances, confusion, or altered mental function), osteonecrosis of the jaw (perform oral examination prior to initiation and periodically during therapy), thyroid dysfunction (assess for signs of thyroid dysfunction at baseline; monitor for signs/symptoms during treatment), wound healing complications, diarrhea, and stomatitis, and for signs/symptoms of adrenal insufficiency (when used in combination with nivolumab). Assess patients for proper oral hygiene practices. Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;">Additional cardiovascular monitoring: Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking (ASCO [Armenian 2017], ESC [Lyon 2022]). BP at each clinical visit (as well as daily home monitoring for first cycle, after dose increases, and every 2 to 3 weeks thereafter); ECG and QTc assessment in patients at moderate- or high-risk of QTc prolongation (assess QTc monthly during the first 3 months and every 3 to 6 months thereafter); baseline echocardiography in high- and very high-risk patients (repeat every 3 months during the first year and every 6 to 12 months thereafter); consider baseline echocardiography in low- and moderate-risk patients (consider repeating every 4 months during the first year for moderate-risk patients and every 6 to 12 months thereafter) (ESC [Lyon 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends hepatitis B virus (HBV) screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F15846442"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Cabozantinib is a potent inhibitor of proinvasive receptor tyrosine kinases (RTKs), including AXL, FLT-3, KIT, MER, MET, RET, ROS1, TIE-2, TRKB, TYRO3, and VEGFR-1, -2, and -3; induces apoptosis of cancer cells and suppresses tumor growth, metastasis, and angiogenesis (Yakes 2011).</p></div>
<div class="block phk drugH1Div" id="F15846444"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~349 L (Cometriq); ~319 L (Cabometyx)</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Following a single 140 mg dose, a 19% increase in the C<sub>max</sub> was observed with the tablet (compared to the capsule), although the difference in AUC was &lt;10%.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ≥99.7% to plasma proteins</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP3A4</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~55 hours (Cometriq); ~99 hours (Cabometyx)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 2 to 5 hours (Cometriq); 3 to 4 hours (Cabometyx)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (~54%; 43% as unchanged drug); urine (~27%)</p></div>
<div class="block phksp drugH1Div" id="F51154230"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Cabozantinib exposure was increased by 81% in subjects with mild impairment (Child-Pugh class A) and by 63% in subjects with moderate impairment (Child-Pugh class B), compared to subjects with normal liver function.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F30134486"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Arkus | Dabatrox | Zanterib</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx | Cometriq</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Cabanib | Caboxen | Cabozanix</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx | Cometriq</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx | Cometriq</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Dabatrox</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx | Cometriq</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx | Cometriq</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx | Cometriq</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx | Cometriq</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Cabotib | Cabozanib | Cazanat</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx | Cometriq</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Aptimetyx</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx | Cometriq</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx | Cometriq</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Dabatrox</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx | Cometriq</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx | Cometriq</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx | Cometriq</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cabometix | Cabometyx</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx | Cometriq</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx | Cometriq</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Cabometyx</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29972759">
<a name="29972759"></a>Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. <i>N Engl J Med</i>. 2018;379(1):54-63. doi:10.1056/NEJMoa1717002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabozantinib-drug-information/abstract-text/29972759/pubmed" id="29972759" target="_blank">29972759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabozantinib-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34237250">
<a name="34237250"></a>Brose MS, Robinson B, Sherman SI, et al. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncol</i>. 2021;22(8):1126-1138. doi:10.1016/S1470-2045(21)00332-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabozantinib-drug-information/abstract-text/34237250/pubmed" id="34237250" target="_blank">34237250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cabometyx.1">
<a name="Cabometyx.1"></a>Cabometyx (cabozantinib) tablet [prescribing information]. Alameda, CA: Exelixis Inc; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cabometyx.2">
<a name="Cabometyx.2"></a>Cabometyx (cabozantinib) [product monograph]. Mississauga, Ontario, Canada: Ipsen Biopharmaceuticals Canada Inc; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27279544">
<a name="27279544"></a>Choueiri TK, Escudier B, Powles T, et al; METEOR investigators. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. <i>Lancet Oncol</i>. 2016;17(7):917-927. doi:10.1016/S1470-2045(16)30107-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabozantinib-drug-information/abstract-text/27279544/pubmed" id="27279544" target="_blank">27279544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26406150">
<a name="26406150"></a>Choueiri TK, Escudier B, Powles T, et al; METEOR Investigators. Cabozantinib versus everolimus in advanced renal-cell carcinoma. <i>N Engl J Med</i>. 2015;373(19):1814-1823. doi:10.1056/NEJMoa1510016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabozantinib-drug-information/abstract-text/26406150/pubmed" id="26406150" target="_blank">26406150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28199818">
<a name="28199818"></a>Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial. <i>J Clin Oncol</i>. 2017;35(6):591-597. doi:10.1200/JCO.2016.70.7398<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabozantinib-drug-information/abstract-text/28199818/pubmed" id="28199818" target="_blank">28199818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33657295">
<a name="33657295"></a>Choueiri TK, Powles T, Burotto M, et al; CheckMate 9ER Investigators. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. <i>N Engl J Med</i>. 2021;384(9):829-841. doi:10.1056/NEJMoa2026982<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabozantinib-drug-information/abstract-text/33657295/pubmed" id="33657295" target="_blank">33657295</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cometriq.1">
<a name="Cometriq.1"></a>Cometriq (cabozantinib) capsule [prescribing information]. Alameda, CA: Exelixis Inc; February 2022.</div>
</li>
<li>
<div class="reference">
                  Cometriq (cabozantinib) capsule [prescribing information]. Alameda, CA: Exelixis Inc; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-George.1">
<a name="George.1"></a>George D, Jonasch E. Systemic therapy of advanced clear cell renal carcinoma. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 23, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33197225">
<a name="33197225"></a>Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline. <i>J Clin Oncol</i>. 2020;38(36):4317-4345. doi:10.1200/JCO.20.02672<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabozantinib-drug-information/abstract-text/33197225/pubmed" id="33197225" target="_blank">33197225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32658626">
<a name="32658626"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. <i>J Clin Oncol</i>. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabozantinib-drug-information/abstract-text/32658626/pubmed" id="32658626" target="_blank">32658626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020; 38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabozantinib-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J</i>. 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabozantinib-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32599410">
<a name="32599410"></a>McGregor BA, Lalani AA, Xie W, et al. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. <i>Eur J Cancer</i>. 2020;135:203-210. doi:10.1016/j.ejca.2020.05.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabozantinib-drug-information/abstract-text/32599410/pubmed" id="32599410" target="_blank">32599410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29045520">
<a name="29045520"></a>Schlumberger M, Elisei R, Müller S, et al. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. <i>Ann Oncol</i>. 2017;28(11):2813-2819. doi:10.1093/annonc/mdx479<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabozantinib-drug-information/abstract-text/29045520/pubmed" id="29045520" target="_blank">29045520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21926191">
<a name="21926191"></a>Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. <i>Mol Cancer Ther.</i> 2011;10(12):2298-2308.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabozantinib-drug-information/abstract-text/21926191/pubmed" id="21926191" target="_blank">21926191</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 87299 Version 242.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
